Table 3.
Characteristics of patients with an EGFR mutation treated with gefitinib.
| Total number | 43 |
|---|---|
| Age (median, range) | 67, 28–92 |
| Gender | |
| Male | 13 |
| Female | 30 |
| Smoking-status | |
| Never | 24 |
| Ex/Current | 19 |
| Pack-years of smokers (median, range) | 33, 2.5–225 |
| Histology | |
| Adenocarcinoma | 42 |
| Squamous cell carcinoma | 1 |
| Clinical stage of NSCLC | |
| IB | 2 |
| IIIA | 1 |
| IIIB | 7 |
| IV | 22 |
| Recurrence | 11 |
| History of chemotherapy before gefitinib treatment | |
| No | 28 |
| Yes | 15 |
| EGFR mutation | |
| Ex18 G719C | 1 |
| Ex19 del | 30 |
| Ex21 L858R | 10 |
| Ex19 del + Ex21L858R | 1 |
| Ex19 del + Ex20 T790M | 1 |
| Chest CT | |
| Normal | 36 |
| Emphysema | 6 |
| Fibrosis | 1 |